<DOC>
	<DOCNO>NCT00701545</DOCNO>
	<brief_summary>As part CSL Behring Canada 's continued commitment ensure safety new low volume preparation Humate-P® , CSL Behring Canada propose conduct prospective , multi-center structure data collection routine management patient von Willebrand disease treat Humate P® ivr Canada . The surveillance non-interventional non-experimental . During observation period , routine medical care patient document . It expect difference safety tolerability Humate-P® ivr compare Humate-P®</brief_summary>
	<brief_title>A Canadian Study Assess Safety Humate-P® Ivr ( Infusion Volume Reduced )</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>Male female patient age ; Patients suffer von Willebrand disease previously treat HumateP® ; Patients able communicate well Investigator his/her representative ; Patients able agree comply study requirement ; Patients provide write sign date informed consent prior study procedure perform . Patients receive investigational drug ≤ 4 week prior start study drug recover side effect therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>von Willebrand disease</keyword>
	<keyword>VWD , Humate-P®</keyword>
	<keyword>Infusion volume reduce</keyword>
	<keyword>ivr</keyword>
</DOC>